Saturday 17 October 2026
Export DRUG’s income statement to Excel — free account
Bright Minds Biosciences Inc.
DRUG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 67.9%, free cash flow fell 124.6% and total debt fell 84.7%, each against the same quarter a year earlier.
51.30
2.91
−5.37%
Follow DRUG
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 15.80 | 3.50 | 1.20 | 0.93 | 23.18 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 44.75 | 23.75 | 6.44 | 79.02 | 97.75 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 25 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | 0.00 | 0.00 | — | — | |||||
| EBT | — | — | — | 0 | (7) | (7) | (12) | (5) | (2) | (9) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | 0 | 0 | (7) | (12) | (5) | (2) | (9) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.05) | (0.28) | (3.80) | (4.75) | (1.47) | (0.48) | (1.27) | |||||
| Cash flow | — | — | — | (0.02) | (0.17) | (3.23) | (4.31) | (1.40) | (0.32) | (0.90) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.02) | (0.17) | (3.23) | (4.31) | (1.40) | (0.32) | (0.90) | |||||
| Book value | — | — | — | 0.08 | 0.00 | 8.56 | 3.34 | 1.32 | 0.94 | 8.53 | |||||
| Shares, m | — | — | — | 1 | 1 | 2 | 2 | 4 | 4 | 7 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | 0 | 0 | (6) | (11) | (5) | (1) | (6) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | 0 | 0 | (6) | (11) | (5) | (1) | (6) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | 15 | 15 | 8 | 5 | 4 | 59 | ||||
| Total debt | — | — | — | — | — | — | 0 | 0 | 0 | 0 | |||||
| Net debt | — | — | — | 0 | (16) | (16) | (9) | (5) | (4) | (59) | |||||
| Shareholders’ equity | — | — | — | 0 | 15 | 15 | 8 | 5 | 4 | 59 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (95.98) | (43.17) | (43.17) | (92.53) | (75.07) | (42.96) | (26.97) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | (18.59) | 93.93 | (169.76) | (99.25) | (83.16) | (45.96) | (27.88) | |||||
Negative figures in brackets.
Charts ten years each
Bright Minds Biosciences Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| VALN Valneva SE Sponsored ADR | $560.4M | 59.7× | 19.4× | −17.29% (below 0%: shrinking) | n/m | −56.05% (below 0%: shrinking) | 15.29% | (76.67%) | Compare |
| STTK Shattuck Labs, Inc. | $555.0M | — (loss-making) | — (loss-making) | −10.31% (below 0%: shrinking) | n/m | +1.01% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VECT VectivBio Holding AG | $545.5M | — (loss-making) | — (loss-making) | — | n/m | — | 91.93% | 0.00% | Compare |
| PBYI Puma Biotechnology, Inc. | $543.0M | 18.2× | 24.2× | +7.75% (above 0%: growing) | +33.33% (above 0%: growing) | −88.45% (below 0%: shrinking) | 77.92% | 13.42% | Compare |
| DRUG Bright Minds Biosciences Inc. | $534.7M | — (loss-making) | — | — | n/m | −124.63% (below 0%: shrinking) | 0.00% | 0.00% | |
| FTH Faeth Therapeutics, Inc. | $532.3M | — (loss-making) | — | — | n/m | −174.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CTMX CytomX Therapeutics, Inc. | $525.1M | — (loss-making) | — (loss-making) | −92.40% (below 0%: shrinking) | n/m | −14.50% (below 0%: shrinking) | 100.00% | (1,677.08%) | Compare |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR | $524.8M | — (loss-making) | — (loss-making) | −7.53% (below 0%: shrinking) | n/m | −31.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ACRS Aclaris Therapeutics, Inc. | $513.7M | — (loss-making) | — (loss-making) | −8.33% (below 0%: shrinking) | n/m | −98.77% (below 0%: shrinking) | 10.80% | (1,487.91%) | Compare |
| Median of peers | $537.7M | — | — | −9.32% | — | −56.05% | 46.61% | 0.00% |
Bright Minds Biosciences Inc. (DRUG) key facts
- Bright Minds Biosciences Inc. (DRUG) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, DRUG traded at $51.30, a market capitalization of $534.7 million.
- Return on equity was −27.9% and debt-to-equity 0.00.